Tags

Type your tag names separated by a space and hit enter

Experimental aerosol survival of SARS-CoV-2 in artificial saliva and tissue culture media at medium and high humidity.
Emerg Microbes Infect. 2020 Dec; 9(1):1415-1417.EM

Abstract

SARS-CoV-2, the causative agent of the COVID-19 pandemic, may be transmitted via airborne droplets or contact with surfaces onto which droplets have deposited. In this study, the ability of SARS-CoV-2 to survive in the dark, at two different relative humidity values and within artificial saliva, a clinically relevant matrix, was investigated. SARS-CoV-2 was found to be stable, in the dark, in a dynamic small particle aerosol under the four experimental conditions we tested and viable virus could still be detected after 90 minutes. The decay rate and half-life was determined and decay rates ranged from 0.4 to 2.27 % per minute and the half lives ranged from 30 to 177 minutes for the different conditions. This information can be used for advice and modelling and potential mitigation strategies.

Authors+Show Affiliations

Chemical Biological and Radiological Division, Defence Science and Technology Laboratory (Dstl), Wiltshire, UK.Chemical Biological and Radiological Division, Defence Science and Technology Laboratory (Dstl), Wiltshire, UK.Chemical Biological and Radiological Division, Defence Science and Technology Laboratory (Dstl), Wiltshire, UK.Chemical Biological and Radiological Division, Defence Science and Technology Laboratory (Dstl), Wiltshire, UK.

Pub Type(s)

Letter

Language

eng

PubMed ID

32496967

Citation

Smither, Sophie J., et al. "Experimental Aerosol Survival of SARS-CoV-2 in Artificial Saliva and Tissue Culture Media at Medium and High Humidity." Emerging Microbes & Infections, vol. 9, no. 1, 2020, pp. 1415-1417.
Smither SJ, Eastaugh LS, Findlay JS, et al. Experimental aerosol survival of SARS-CoV-2 in artificial saliva and tissue culture media at medium and high humidity. Emerg Microbes Infect. 2020;9(1):1415-1417.
Smither, S. J., Eastaugh, L. S., Findlay, J. S., & Lever, M. S. (2020). Experimental aerosol survival of SARS-CoV-2 in artificial saliva and tissue culture media at medium and high humidity. Emerging Microbes & Infections, 9(1), 1415-1417. https://doi.org/10.1080/22221751.2020.1777906
Smither SJ, et al. Experimental Aerosol Survival of SARS-CoV-2 in Artificial Saliva and Tissue Culture Media at Medium and High Humidity. Emerg Microbes Infect. 2020;9(1):1415-1417. PubMed PMID: 32496967.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Experimental aerosol survival of SARS-CoV-2 in artificial saliva and tissue culture media at medium and high humidity. AU - Smither,Sophie J, AU - Eastaugh,Lin S, AU - Findlay,James S, AU - Lever,Mark S, PY - 2020/6/5/pubmed PY - 2020/6/25/medline PY - 2020/6/5/entrez KW - SARS-CoV-2 KW - aerosol KW - coronavirus KW - humidity KW - saliva KW - survival SP - 1415 EP - 1417 JF - Emerging microbes & infections JO - Emerg Microbes Infect VL - 9 IS - 1 N2 - SARS-CoV-2, the causative agent of the COVID-19 pandemic, may be transmitted via airborne droplets or contact with surfaces onto which droplets have deposited. In this study, the ability of SARS-CoV-2 to survive in the dark, at two different relative humidity values and within artificial saliva, a clinically relevant matrix, was investigated. SARS-CoV-2 was found to be stable, in the dark, in a dynamic small particle aerosol under the four experimental conditions we tested and viable virus could still be detected after 90 minutes. The decay rate and half-life was determined and decay rates ranged from 0.4 to 2.27 % per minute and the half lives ranged from 30 to 177 minutes for the different conditions. This information can be used for advice and modelling and potential mitigation strategies. SN - 2222-1751 UR - https://www.unboundmedicine.com/medline/citation/32496967/Experimental_aerosol_survival_of_SARS_CoV_2_in_artificial_saliva_and_tissue_culture_media_at_medium_and_high_humidity_ L2 - https://www.tandfonline.com/doi/full/10.1080/22221751.2020.1777906 DB - PRIME DP - Unbound Medicine ER -